NCT05629338View on ClinicalTrials.gov

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

March 18, 2025

Study Completion Date

April 29, 2025

Conditions
CoagulopathyHemorrhage
Interventions
COMBINATION_PRODUCT

Autologous Spray Dried Plasma

Evaluation of the Safety of Ascending Doses of Autologous Spray Dried Plasma in Healthy Volunteers

Trial Locations (3)

53095

Spaulding Clinical Research LLC, West Bend

53233

Versiti Blood Center of Wisconsin, Milwaukee

45267-0055

Hoxworth Blood Center, Cincinnati

Sponsors

Lead Sponsor

Velico Medical
All Listed Sponsors
lead

Velico Medical

INDUSTRY

NCT05629338 - Ascending Dose Study of FrontlineODP™ Spray Dried Plasma | Biotech Hunter | Biotech Hunter